Terms: = Ovarian cancer AND RAD51B, ENSG00000182185, 5890, RAD51L1, O15315, hREC2, R51H2, REC2, MGC34245 AND Treatment
6 results:
1. Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer.
Coelho R; Tozzi A; Disler M; Lombardo F; Fedier A; López MN; Freuler F; Jacob F; Heinzelmann-Schwarz V
Cell Death Dis; 2022 Oct; 13(10):909. PubMed ID: 36307400
[TBL] [Abstract] [Full Text] [Related]
2. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
Leibowitz BD; Dougherty BV; Bell JSK; Kapilivsky J; Michuda J; Sedgewick AJ; Munson WA; Chandra TA; Dry JR; Beaubier N; Igartua C; Taxter T
BMC Cancer; 2022 May; 22(1):587. PubMed ID: 35643464
[TBL] [Abstract] [Full Text] [Related]
3. Homologous Recombination Deficiency: cancer Predispositions and treatment Implications.
Toh M; Ngeow J
Oncologist; 2021 Sep; 26(9):e1526-e1537. PubMed ID: 34021944
[TBL] [Abstract] [Full Text] [Related]
4. Whole-genome characterization of chemoresistant ovarian cancer.
Patch AM; Christie EL; Etemadmoghadam D; Garsed DW; George J; Fereday S; Nones K; Cowin P; Alsop K; Bailey PJ; Kassahn KS; Newell F; Quinn MC; Kazakoff S; Quek K; Wilhelm-Benartzi C; Curry E; Leong HS; ; Hamilton A; Mileshkin L; Au-Yeung G; Kennedy C; Hung J; Chiew YE; Harnett P; Friedlander M; Quinn M; Pyman J; Cordner S; O'Brien P; Leditschke J; Young G; Strachan K; Waring P; Azar W; Mitchell C; Traficante N; Hendley J; Thorne H; Shackleton M; Miller DK; Arnau GM; Tothill RW; Holloway TP; Semple T; Harliwong I; Nourse C; Nourbakhsh E; Manning S; Idrisoglu S; Bruxner TJ; Christ AN; Poudel B; Holmes O; Anderson M; Leonard C; Lonie A; Hall N; Wood S; Taylor DF; Xu Q; Fink JL; Waddell N; Drapkin R; Stronach E; Gabra H; Brown R; Jewell A; Nagaraj SH; Markham E; Wilson PJ; Ellul J; McNally O; Doyle MA; Vedururu R; Stewart C; Lengyel E; Pearson JV; Waddell N; deFazio A; Grimmond SM; Bowtell DD
Nature; 2015 May; 521(7553):489-94. PubMed ID: 26017449
[TBL] [Abstract] [Full Text] [Related]
5. Human DNA helicase HELQ participates in DNA interstrand crosslink tolerance with ATR and RAD51 paralogs.
Takata K; Reh S; Tomida J; Person MD; Wood RD
Nat Commun; 2013; 4():2338. PubMed ID: 24005565
[TBL] [Abstract] [Full Text] [Related]
6. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.
Ihnen M; zu Eulenburg C; Kolarova T; Qi JW; Manivong K; Chalukya M; Dering J; Anderson L; Ginther C; Meuter A; Winterhoff B; Jones S; Velculescu VE; Venkatesan N; Rong HM; Dandekar S; Udar N; Jänicke F; Los G; Slamon DJ; Konecny GE
Mol Cancer Ther; 2013 Jun; 12(6):1002-15. PubMed ID: 23729402
[TBL] [Abstract] [Full Text] [Related]
